Rigel has agreed to pay the Licensors an upfront payment of $70 million and an additional $15 million upon the successful completion of certain transition activities.
Rigel has agreed to pay the Licensors an upfront payment of $70 million and an additional $15 million upon the successful completion of certain transition activities.
Rigel has agreed to pay the Licensors an upfront payment of $70 million and an additional $15 million upon the successful completion of certain transition activities.
In connection with the transition of the Licensed Products, Pfizer will continue to be responsible for certain ongoing development activities, and Rigel has agreed to reimburse the Licensors for cert…
nt assistance programs. Numerous organizations, including pharmaceutical manufacturers, have been subject to ongoing litigation, enforcement activities and settlements related to their patient suppor…
Reciprocal relationship from ORANY graph: Reciprocal relationship from RIGL graph: nt assistance programs. Numerous organizations, including pharmaceutical manufacturers, have been subject to ongoing…
Reciprocal relationship from CAH graph: Reciprocal relationship from RIGL graph: ivable (as it relates to allowance for prompt pay discount) and prepaid and other current assets (as it relates to cer…
ivable (as it relates to allowance for prompt pay discount) and prepaid and other current assets (as it relates to certain chargebacks and other fees that were prepaid) in the balance sheet. The foll…
onouncements For a discussion of recent accounting pronouncements, see “Note 1– Description of Business and Summary of Significant Accounting Policies”, in the “Notes to Financial Statements” contain…
Reciprocal relationship from MCK graph: Reciprocal relationship from RIGL graph: onouncements For a discussion of recent accounting pronouncements, see “Note 1– Description of Business and Summary of…
al sale of any of our product candidates. If any or all of them become subject to adverse findings from inspections or face other difficulties to operate, then the distribution of our products may be…
Reciprocal relationship from LLY graph: Reciprocal relationship from RIGL graph: al sale of any of our product candidates. If any or all of them become subject to adverse findings from inspections or…
Reciprocal relationship from ORANY graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from ORAN…
nd incident reporting requirements on ‘essential’ and ‘important’ entities, which include ICT managed service providers (MSP), cloud service providers as well as entities carrying out research and de…
Reciprocal relationship from SNYNF graph: Reciprocal relationship from RIGL graph: al sale of any of our product candidates. If any or all of them become subject to adverse findings from inspections …
al sale of any of our product candidates. If any or all of them become subject to adverse findings from inspections or face other difficulties to operate, then the distribution of our products may be…
Reciprocal relationship from VOR graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from VOR graph: Reciprocal relationship from RIGL graph: Reciprocal relationship from VOR grap…
Rigel Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
RIGL-DEBT
Debt stack $45.7M
90%
Market cache reports total debt of $45.7M.
Rigel Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Rigel Pharmaceuticals, Inc..
Rigel Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
RIGL-OWNER-QUINN-OPPORTUNITY-PARTNERS-LLC
Quinn Opportunity Partners LLC
90%
13F overlay lists Quinn Opportunity Partners LLC as top holder; 13 tracked holders.
Rigel Pharmaceuticals, Inc. Extended Supply Chain Network
